key: cord-1002047-y28xzo3o authors: Ricks, S.; Kendall, E. A.; Dowdy, D. W.; Sacks, J. A.; Schumacher, S. G.; Arinaminpathy, N. title: Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis date: 2020-11-23 journal: nan DOI: 10.1101/2020.11.20.20235317 sha: 4944a578d4603582fdc67904cc4b6e7fec23a4e1 doc_id: 1002047 cord_uid: y28xzo3o Background: Testing plays a critical role in treatment and prevention responses to the COVID-19 pandemic. Compared to nucleic acid tests (NATs), antigen-detection rapid diagnostic tests (Ag-RDTs) can be more accessible, but typically have lower sensitivity and specificity. By quantifying these trade-offs, we aimed to inform decisions about when an Ag-RDT would offer greater public health value than reliance on NAT. Methods: Following an expert consultation, we selected two use cases for analysis: rapid identification of people with COVID-19 amongst patients admitted with respiratory symptoms in a hospital setting; and early identification and isolation of people with mildly symptomatic COVID-19 in a community setting. Using decision analysis, we evaluated the cost and impact (deaths averted and infectious days isolated) of an Ag-RDT-led strategy, compared to a strategy based on NAT and clinical judgment. We performed a multivariate sensitivity analysis to identify key parameters. Results: In a hospital setting, an Ag-RDT-led strategy would avert more deaths than a NAT-based strategy, and at lower cost per death averted, when the sensitivity of clinical judgement is less than 85%, and when NAT results are available in time to inform clinical decision-making for less than 90% of patients. The use of an Ag-RDT is robustly supported in community settings, where it would avert more transmission at lower cost than relying on NAT alone, under a wide range of assumptions. Conclusions: Despite their imperfect sensitivity and specificity, Ag-RDTs have the potential to be simultaneously more impactful, and cost-effective, than current approaches to COVID-19 diagnostic testing. For both use cases we constructed decision trees ( Figure 1 ) that represent the diagnostic use of of symptomatic versus pre-or asymptomatic cases, that are not specified in our model. Our 27 focus is therefore on the direct benefits that would accrue to patients receiving the test and, by 28 extension, their immediate contacts (see right-hand column of Table 1 ). Model parameters, listed in Table 2 , represent the contextual factors to be examined (including 31 plausible ranges for each), with the aim of identifying those factors that are most influential for 32 the value of an Ag-RDT-led testing strategy relative to NAT-based testing. Our expert 33 consultation highlighted that no standard guidance for whether or how Ag-RDTs should be used . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235317 doi: medRxiv preprint 1 It is also necessary to specify scenarios for interim management of patients while awaiting a 2 NAT result (whether in the NAT-based strategy or while awaiting NAT confirmation in an Agthis time: in the supporting information we also present sensitivity analysis, to the alternative 6 scenario where there is no isolation, nor treatment pending NAT results. By contrast, in the 7 community setting we assumed that individuals are not isolated while awaiting any NAT result, 8 as this policy was considered infeasible due to the comparatively low prevalence of COVID-19 9 in this population, and the unnecessary expense and disruption this would entail to most tested 10 individuals and their families. Although NAT specificity is near 100% for current or recent infection (15) , not all NAT-positive 13 cases are necessarily infectious, given the potential to detect unviable viral genetic material 14 after the infection has resolved (15) (16) (17) and for severe symptoms to develop near the end of the 15 infectious period (18) . By contrast, Ag-RDTs may detect only acute, but not recently cleared, infection (19, 20) . These distinctions have significance for the intended purpose of the test: where the purpose is to guide clinical decisions for treatment, knowing the aetiology of severe 18 symptoms is important, regardless of viral antigenic load. On the other hand, where the purpose 19 is early identification of infectious cases, detecting recently-cleared infection can detract from 20 the utility of a test. We captured these elements of both NATs and Ag-RDTs by distinguishing 21 'acute' from 'recent' infection, and assuming that: (i) only acute infection is infectious; (ii) NAT is able to detect both acute and recent infection with equal sensitivity, and (iii) an Ag-RDT is able 23 to detect only acute infection (19) . As discussed below, although these are useful simplifications 24 for the purpose of the current analysis, these categorisations conceal potentially important 25 complexities relating to temporal and between-individual variation in viral load, infectivity and 26 detectability by a given test. In the present analysis we incorporated a parameter for the 27 proportion of those with COVID-19, amongst the population being tested, that are still in the 28 acute phase at the point of testing, allowing this parameter to occupy a wide range of values 29 between 50% and 100%, acknowledging the existing uncertainty (See Table 2 ). Quantifying relative value 32 33 To estimate the impact of a test on deaths in a hospital setting, we assumed that a certain 34 proportion of admitted patients would die without treatment. We assumed that early treatment of 35 these individuals would reduce mortality by 5 -50% (Table 2) , consistent with recent study 36 results for corticosteroid treatment of COVID-19 (7) . We assumed further that individuals with 37 severe disease would be eligible for treatment while awaiting a test result, as well as once 38 confirmed as having COVID-19. We thus denoted 'deaths averted' as the reduction in deaths 39 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235317 doi: medRxiv preprint that would be achieved by a given testing strategy, relative to no intervention. Similarly, as a 1 simple proxy for the impact of a test on transmission, we first assumed a uniform distribution for the number of infectious days remaining per patient amongst patients presenting with acute 3 infection (Table 2) . We then recorded the number of patient-days of acute infection that were 4 not spent in isolation, whether because of missed diagnosis or (in the case of NAT) delayed diagnosis without isolation, while awaiting a test result. We denoted 'infectious person-days 6 averted' as the reduction that would be achieved by a given testing strategy, relative to no 7 intervention. Using the model illustrated in Figure 1 , we estimated the impact (deaths or infectious days averted) and cost of each testing strategy. We stratified Ag-RDT-led strategies by the adjunctive To compare testing strategies, we first estimated the cost-per-death averted (in the hospital 24 setting), and the cost-per-infectious person day isolated (in both hospital and community 25 settings) under NAT-based and Ag-RDT-led strategies. However, we did not aim to determine 26 whether or not an Ag-RDT would be cost-effective, given the uncertainties surrounding 27 appropriate willingness-to-pay thresholds for emergency outbreak response (21). Instead, we 28 compared the two strategies (Ag-RDT vs NAT) using a simple approach of plotting their relative 29 impact against their relative cost for each sampled set of parameters (see Figure S1 for a 30 schematic illustration of the approach). It is important to note that this approach is distinct from a 31 conventional cost-effectiveness plane, as the axes are shown on a relative, rather than a 32 nominal, scale. In the example of deaths, we denoted "#$ as the deaths averted by Ag-RDT-33 led testing, relative to no intervention, and likewise for %&$ . Similarly, we calculated the 34 incremental cost "#$ of an Ag-RDT-led strategy relative to no intervention, and likewise for 35 %&$ . We then plotted the relative impact ( "#$ / %&$ ) against the relative incremental cost . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235317 doi: medRxiv preprint We defined an Ag-RDT as being 'favourable' relative to NAT, wherever its use results 1 simultaneously in more deaths averted than NAT (i.e. "#$ > %&$ ), and a lower incurred cost 2 per death averted than NAT (i.e. "#$ / "#$ < %&$ / %&$ ). We defined an Ag-RDT as being 3 'non-favourable' otherwise. We performed corresponding calculations for the outcome of 4 infectious person-days successfully isolated. Our focus in the following analysis is on identifying 5 which circumstances would lead to an Ag-RDT being 'favourable' relative to NAT. Where simulation outputs were equivocal on the favourability of Ag-RDTs, i.e. straddling 8 favourable and non-favourable regions, we evaluated the correlation between each parameter 9 and relevant model outputs using partial rank correlation coefficients, to identify those 10 parameters that were most influential on the probability of a simulation falling in a favourable Role of the funding source grant from the World Health Organization (WHO). Authors JS and SS are employees of FIND. Otherwise, neither FIND nor WHO had no role in the study design, analysis or interpretation. Table S2 shows estimates of incremental cost-effectiveness ratios (relative to a scenario of no 26 intervention), illustrating, for example, that -relative to no intervention -a NAT based algorithm is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235317 doi: medRxiv preprint missed cases to exceed the impact of NAT-based strategies in more than 99% of simulations. For settings in which NAT is used to confirm Ag-RDT-negative results, Fig. 2B illustrates the relationship of each model parameter to the probability of a "favourable" simulation. In particular, 3 the availability of NAT, sensitivity of clinical judgment amongst those unable to access NAT, and 4 proportion of cases tested during the acute phase were highly influential. Community Screening Finally, Fig.4 shows results for the community screening scenario. Key assumptions, compared 32 to the hospital scenario, include: the sole priority is to avert infection, because mortality risk in tested (5%); and we assume individuals are not placed in isolation while awaiting NAT results, because of the infeasibility of doing so. Similarly to Fig.3 , confirming Ag-RDT-negative cases 36 with NAT is highly likely to avert more potential transmission than NAT alone, and at lower cost 37 per infectious day averted (blue points, favourable in 100% of simulations). It is also possible for 38 the sole use of Ag-RDT to be more impactful than NAT while costing less (yellow points, 39 favourable in 99% of simulations). Fig. 4B illustrates that key drivers that would tend to increase is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235317 doi: medRxiv preprint NAT; and a lower sensitivity of clinical judgement. Because the vast majority of simulations 1 place the Ag-RDT in the favourable region, we do not present the bivariate sensitivity analyses 2 that was necessary for the hospital setting scenarios (Figs. 2C, 3C ). The emergence of antigen-detection rapid diagnostic tests for SARS-CoV-2 has raised 7 important questions about trade-offs between accessibility and performance. Recent models 8 and commentaries have highlighted the potential utility of high-frequency, low-sensitivity testing of asymptomatic individuals (22) , and the current analysis demonstrates that under certain circumstances, a less-sensitive but more-accessible test may be preferable for diagnosis of 11 symptomatic COVID-19 as well. In this work we have sought to quantify these trade-offs in a Ag-RDT. Our results suggest that the value of an Ag-RDT-led strategy is strongly supported for evaluating symptomatic individuals in community settings, being highly likely to be 23 simultaneously less costly and more impactful than relying on NAT and clinical judgement (Fig. 24 4 ). In hospital settings, the favourability of Ag-RDT may be subject to certain qualifications. For 25 example, in averting deaths, an Ag-RDT, supported by NAT to confirm Ag-RDT-negative 26 results, is likely to be favourable (averting more deaths, at less cost per death averted) to NAT 27 and clinical judgment alone, in settings where NAT is available for less than 85% of patients, 28 and sensitivity of clinical judgement (in the absence of NAT) is less than 90% (Fig. 2 ). We note that in the community setting in particular, any reliance on NAT-based testing would 31 face substantial challenges in practice. For example, in most settings it is unlikely that 32 individuals would be adequately isolated while awaiting NAT results, given the large number of 33 unnecessary isolations, and associated burden on patients and families, that such a strategy 34 would incur. Moreover, it will also typically be infeasible to offer timely NAT to all individuals with 35 potential COVID-19 symptoms, given the attendant financial, human resource and supply 36 constraints. In this setting, our analysis shows how an affordable, rapid test, even one with 37 lower performance than NAT, can achieve greater impact overall, and at lower cost, than a 38 strategy that relies on NAT instead. Notably in both hospital and community scenarios, the key determining factors for the value of 41 an Ag-RDT (namely, the availability of NAT, sensitivity of clinical judgment, and proportion of 42 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235317 doi: medRxiv preprint cases tested during the acute phase) all relate to the ability of the existing system to detect 1 cases of SARS-CoV-2. These findings highlight the potential value of implementation studies to gather data on these factors when making programmatic decisions for the introduction and 3 implementation of new Ag-RDTs in any given setting. Overall, this work serves broadly to 4 illustrate an analytical framework that could be readily adjusted to local realities in different 5 settings. A simple, user-friendly web-based tool is available, to perform the simulations shown 6 here, but also to allow these simulations to be extended to alternative, user-specified parameter 7 ranges (https://covid-ag-rdt.shinyapps.io/model/). Certain limitations of scope bear mention. Our focus in this work is on identifying the circumstances in which an Ag-RDT might be most valuable, given a pre-specified performance 11 profile. Recent guidance published by WHO addresses target product profiles for Ag-RDTs: that 12 is, how a test should best be optimised in terms of accuracy, cost and ease-of-use, for specified 13 use cases (11) . For simplicity, our approach treats transmission-related impact of testing as (16, (23) (24) (25) (26) . Previous modelling studies have 29 incorporated some combinations of these factors (3, 22) , but longitudinal data on all of these 30 factors will be critical in refining these and other modelling approaches, to account fully for their 31 potential interactions. In summary, given the immediate importance of virological testing for the control of SARS-CoV- is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235317 doi: medRxiv preprint outcomes, at more favourable cost-effectiveness ratios, than reliance on NAT and clinical 1 judgment alone. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 23, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235317 doi: medRxiv preprint 1 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235317 doi: medRxiv preprint Figure 4 . Relative value of Ag-RDT vs NAT testing in a community setting. We assume 3 that in a community setting, the focus is on averting infection, and that any severe cases of 4 respiratory disease are more likely to present in hospital settings (Fig. 3) . Hence in this setting, 5 we focus on infectious person-days averted; we also assume that individuals awaiting NAT 14 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Ag-RDT sensitivity for current infection (%, assumed only amongst acute cases) 0.80 0.80 (13, 14) Ag-RDT specificity (%) 0.98 0.98 (13, 14) Cost per Ag-RDT test ($) 5 5 Sensitivity of clinical judgment in absence of NAT 0.45 -0.99 0.45 -0.99 (32) (33) (34) (35) Specificity of clinical judgment in absence of NAT 0.20 -0.50 0.20 -0.50 (32) (33) (34) (35) Amongst those who would survive without treatment (including COVID -ve and COVID +ve), 0 -0.1 N/A . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235317 doi: medRxiv preprint proportion erroneously identified as needing treatment Amongst COVID +ve who would die without treatment, proportion correctly identified as such 0.8 -1 N/A Duration of isolation (days) 10 10 (27) Duration of treatment (days) 10 N/A Cost of isolation per day ($) 10 -100 10 -100 Cost of treatment per day ($) 50 -500 N/A (36,37) 1 result, we assume that they do not receive any benefits of interim treatment. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235317 doi: medRxiv preprint World Health Organisation. WHO COVID-19 Preparedness and Response Progress Report -1 Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2 Imperial College COVID-19 response team. Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. Open Forum Infect Dis Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results South Africa's coronavirus testing strategy is broken and not fit for purpose: It's time for a change COVID-19: Are Africa's diagnostic challenges blunting response effectiveness? World Health Organisation. COVID-19 Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0 Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection World Health Organisation. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays USA: FDA; 2020. (Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations for Medical Devices Interpreting Diagnostic Tests for SARS-CoV-2 Virological assessment of hospitalized patients with COVID-2019 Retest positive for SARS-CoV-2 RNA of "recovered" patients with COVID-19: Persistence, sampling issues, or re-infection Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States Antigen-based testing but not real-time PCR correlates with SARS-CoV-2 virus culture From more testing to smart testing: data-guided SARS-CoV-2 testing choices Economic Considerations in Infectious Diseases Emergency Response Preparedness: It's All About the Point of View Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China SARS-CoV-2 detection, viral load and infectivity over the course of an infection Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing Temporal dynamics in viral shedding and transmissibility of COVID-19 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet Estimates of the severity of coronavirus disease 2019: a model-based analysis Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Compassionate Use of Remdesivir for Patients with Severe Covid-19 Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan Epidemiological and Clinical Predictors of COVID-19 Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019 Diagnostic Performance of CT and Reverse Transcriptase-Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis Gilead prices COVID-19 drug remdesivir at $2,340 per patient in developed nations Q&A: Dexamethasone and COVID-19